Enanta Pharmaceuticals, Inc.

ENTA

$13.84

Name : Enanta Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $401,616,352.00

EPSttm : -3.21

Enanta Pharmaceuticals, Inc.

$13.84

2.88%

$0.41

Float Short %

8.19

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

EPS Last/This Y

1.02

EPS This/Next Y

0.21

Price

14.27

Target Price

17.8

Analyst Recom

1.6

Performance Q

23.81

Relative Volume

0.68

Beta

0.98

Ticker: ENTA

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	ENTA	13.11	0.13	0.00	2754
2026-01-14	ENTA	13.86	0.12	999.99	2802
2026-01-15	ENTA	13.35	0.12	0.15	2805
2026-01-16	ENTA	12.6	0.11	0.00	2798
2026-01-20	ENTA	12.51	0.08	0.16	1084
2026-01-21	ENTA	12.58	0.08	12.00	1149
2026-01-22	ENTA	12.83	0.12	4.00	1188
2026-01-23	ENTA	13.03	0.13	0.00	1206
2026-01-26	ENTA	12.91	0.12	100.00	1279
2026-01-27	ENTA	13.03	0.21	0.00	1378
2026-01-28	ENTA	12.66	0.21	35.00	1381
2026-01-29	ENTA	12.95	0.27	0.00	1452
2026-01-30	ENTA	12.81	0.27	999.99	1452
2026-02-02	ENTA	13.21	0.28	0.00	1462
2026-02-03	ENTA	13.55	0.28	2.50	1461
2026-02-04	ENTA	13.45	0.28	0.00	1464
2026-02-05	ENTA	12.98	0.28	0.00	1464
2026-02-06	ENTA	13.53	0.27	0.00	1526
2026-02-09	ENTA	13.81	0.27	1.00	1527
2026-02-10	ENTA	14.12	0.27	0.06	1527
2026-02-11	ENTA	14.23	0.27	0.00	1528
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	ENTA	13.12	23.1	-	-3.07
2026-01-14	ENTA	13.85	23.1	-	-3.07
2026-01-15	ENTA	13.38	23.1	-	-3.07
2026-01-16	ENTA	12.61	23.1	-	-3.07
2026-01-20	ENTA	12.50	23.1	-	-3.07
2026-01-21	ENTA	12.56	23.1	-	-3.07
2026-01-22	ENTA	12.81	23.1	-	-3.07
2026-01-23	ENTA	13.02	23.1	-	-3.07
2026-01-26	ENTA	12.94	23.1	-	-3.07
2026-01-27	ENTA	12.98	23.1	-	-3.07
2026-01-28	ENTA	12.67	23.1	-	-3.07
2026-01-29	ENTA	12.91	23.1	-	-3.07
2026-01-30	ENTA	12.90	16.6	-	-3.09
2026-02-02	ENTA	13.22	16.6	-	-3.09
2026-02-03	ENTA	13.54	16.6	-	-3.09
2026-02-04	ENTA	13.46	16.6	-	-3.09
2026-02-05	ENTA	12.98	16.6	-	-3.09
2026-02-06	ENTA	13.49	16.6	-	-3.09
2026-02-09	ENTA	13.86	16.6	-	-3.09
2026-02-10	ENTA	14.10	16.6	-	-3.09
2026-02-11	ENTA	14.27	16.6	-	-2.82
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	ENTA	-0.88	15.46	7.60
2026-01-14	ENTA	-0.88	15.46	7.60
2026-01-15	ENTA	-0.88	15.46	7.60
2026-01-16	ENTA	-0.88	15.46	7.60
2026-01-20	ENTA	-0.88	15.33	7.60
2026-01-21	ENTA	-0.88	15.33	7.60
2026-01-22	ENTA	-0.88	15.33	7.60
2026-01-23	ENTA	-0.88	15.33	7.60
2026-01-26	ENTA	-0.88	16.50	7.60
2026-01-27	ENTA	-0.88	16.50	7.60
2026-01-28	ENTA	-0.88	16.50	8.22
2026-01-29	ENTA	-0.88	16.50	8.22
2026-01-30	ENTA	-0.88	16.50	8.22
2026-02-02	ENTA	-0.88	16.46	8.17
2026-02-03	ENTA	-0.89	16.46	8.17
2026-02-04	ENTA	-0.89	16.46	8.17
2026-02-05	ENTA	-0.89	16.46	8.17
2026-02-06	ENTA	-0.89	16.46	8.17
2026-02-10	ENTA	-0.89	19.57	8.17
2026-02-11	ENTA	-0.89	19.57	8.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.69

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-0.89

Institutional Transactions

19.57

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-95.6

Target Price

17.8

P/E

Forward P/E

PEG

P/S

6.17

P/B

4.71

P/Free Cash Flow

EPS

-3.2

Average EPS Est. Cur. Y

-2.82

EPS Next Y. (Est.)

-2.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-106.8

Relative Volume

0.68

Return on Equity vs Sector %

-154.4

Return on Equity vs Industry %

-138

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.24

EBIT Estimation

Enanta Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 120

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today

news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance

stock history ENTA – Enanta Pharmaceuticals Inc invest stock market

stock prices ENTA premarket after hours

ticker ENTA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ENTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y